Publicaciones en las que colabora con RAFAEL SAN JUAN GARRIDO (18)

2024

  1. Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 313-324

2023

  1. Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial

    BMJ open, Vol. 13, Núm. 9, pp. e072121

2022

  1. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

    International Journal of Infectious Diseases, Vol. 117, pp. 56-64

2021

  1. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

    International Journal of Infectious Diseases, Vol. 105, pp. 487-494

  2. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

    International Journal of Infectious Diseases, Vol. 105, pp. 319-325

  3. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

    Journal of Medical Virology, Vol. 93, Núm. 2, pp. 831-842

2018

  1. Comparison of the clinical course of Clostridium difficile infection in glutamate dehydrogenase-positive toxin-negative patients diagnosed by PCR to those with a positive toxin test

    Clinical Microbiology and Infection, Vol. 24, Núm. 4, pp. 414-421

  2. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study

    Transplant International, Vol. 31, Núm. 2, pp. 187-197

  3. Impact on mortality of adherence to evidence-based interventions in patients with catheter-related bloodstream infection due to methicillin-sensitive Staphylococcus aureus

    Infectious Diseases, Vol. 50, Núm. 11-12, pp. 837-846

  4. Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?

    Atherosclerosis, Vol. 269, pp. 204-210

2017

  1. Serum sCD30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation

    Transplant Infectious Disease, Vol. 19, Núm. 2

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

  2. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  3. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

  4. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options

    Transplant Infectious Disease, Vol. 18, Núm. 4, pp. 575-584

  5. Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial

    American Journal of Transplantation, Vol. 16, Núm. 10, pp. 2943-2953

2015

  1. Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case–control study

    Infection, Vol. 43, Núm. 4, pp. 413-422

2012

  1. Clinical significance of Candida colonization of intravascular catheters in the absence of documented candidemia

    Diagnostic Microbiology and Infectious Disease, Vol. 73, Núm. 2, pp. 157-161